Home › Funds › Polar Capital Holdings Plc › ELVN
Polar Capital Holdings Plc position in ELVN
ENLIVEN THERAPEUTICS INC · Health Care
Polar Capital Holdings Plc reported holding 6,430,636 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$326.4M, representing 0.94% of its reported portfolio and ranking #27 among its reported holdings. Polar Capital Holdings Plc has disclosed ELVN holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Polar Capital Holdings Plc's ELVN position evolved
Polar Capital Holdings Plc first disclosed a stake in ELVN in Q2 2024 at 650,000 shares (US$15.2M). The position peaked in Q2 2026 at 6,430,636 shares, worth US$326.4M. Across 9 filings, Polar Capital Holdings Plc increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 6,430,636 shares valued at US$326.4M — an increase of 1,364,703 shares quarter over quarter.. Notable position changes include a 268% increase in Q4 2024 (shares fell 13% over the following quarter), a 29% increase in Q2 2025 (shares rose 2% over the following quarter), a 44% increase in Q1 2026 (shares rose 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 650.00K | $15.19M | New |
| Q3 2024 | 650.00K | $16.60M | Hold |
| Q4 2024 | 2.39M | $53.77M | Add |
| Q1 2025 | 2.37M | $46.55M | Reduce |
| Q2 2025 | 3.05M | $61.19M | Add |
| Q3 2025 | 3.10M | $63.35M | Add |
| Q4 2025 | 3.51M | $54.11M | Add |
| Q1 2026 | 5.07M | $198.58M | Add |
| Q2 2026 | 6.43M | $326.35M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ELVN and 13F data
ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 67 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Vestal Point Capital, LP (US$203.0M), Commodore Capital LP (US$166.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ELVN
- ORBIMED ADVISORS LLC 6.78M sh · $343.91M · Q2 2026
- Vestal Point Capital, LP 4.00M sh · $203.00M · Q2 2026
- Commodore Capital LP 3.27M sh · $166.21M · Q2 2026
- Fairmount Funds Management LLC 1.86M sh · $94.17M · Q2 2026
- Siren, L.L.C. 1.77M sh · $90.05M · Q2 2026
- Bellevue Group AG 1.49M sh · $75.62M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $69.06M · Q2 2026
- Novo Holdings A/S 1.00M sh · $50.75M · Q2 2026
- First Turn Management, LLC 954.36K sh · $48.43M · Q2 2026
- SAMLYN CAPITAL, LLC 912.64K sh · $46.32M · Q2 2026
- BAKER BROS. ADVISORS LP 905.19K sh · $45.94M · Q2 2026
- Tri Locum Partners LP 866.72K sh · $43.99M · Q2 2026
More on Polar Capital Holdings Plc
FAQ
How long has Polar Capital Holdings Plc held ELVN?
Polar Capital Holdings Plc has disclosed ELVN holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
What is Polar Capital Holdings Plc's current position in ELVN?
As of Q2 2026, Polar Capital Holdings Plc holds 6.43M shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $326.35M, representing 0.94% of its reported portfolio and ranking #27.
Has Polar Capital Holdings Plc been buying or selling ELVN?
In the latest 13F filing (Q2 2026), Polar Capital Holdings Plc increased its position in ELVN. The position peaked in Q2 2026 at 6.43M shares.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Vestal Point Capital, LP, Commodore Capital LP, among 67 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.